Improvement of ketamine-induced social withdrawal in rats: The role of 5-HT7 receptors

Behavioural Pharmacology

Volumn 26, Issue 8, 2015, Pages 766-775

  Hołuj, Małgorzata ^a   Popik, Piotr ^a   Nikiforuk, Agnieszka ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

5 HT7 receptors; Amisulpride; antipsychotics; ketamine; rat; schizophrenia; social behaviour

Indexed keywords

3 [2 [2 (4 METHYL 1 PIPERIDINYL)ETHYL] 1 PYRROLIDINESULFONYL]PHENOL; AMISULPRIDE; CHLORDIAZEPOXIDE; FLUOXETINE; HALOPERIDOL; KETAMINE; SEROTONIN 7 RECEPTOR; SULPIRIDE; AMINO ACID RECEPTOR BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; PHENOL DERIVATIVE; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR; SULFONAMIDE; SULTOPRIDE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; IN VITRO STUDY; LOCOMOTION; MALE; NEGATIVE SYNDROME; NONHUMAN; PSYCHOSOCIAL WITHDRAWAL; RAT; SCHIZOPHRENIA; SOCIAL INTERACTION; ANALOGS AND DERIVATIVES; ANIMAL; ANIMAL BEHAVIOR; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; METABOLISM; SOCIAL BEHAVIOR DISORDERS; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; EXCITATORY AMINO ACID ANTAGONISTS; KETAMINE; MALE; PHENOLS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; RECEPTORS, SEROTONIN; SCHIZOPHRENIA; SEROTONIN ANTAGONISTS; SOCIAL BEHAVIOR DISORDERS; SULFONAMIDES; SULPIRIDE;

EID: 84939963547     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0000000000000132     Document Type: Article

References (50)

1. Abbas AI, Hedlund PB, Huang XP, Tran TB, Meltzer HY, Roth BL (2009). Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology (Berl) 205:119-128.
2. Arango C, Garibaldi G, Marder SR (2013). Pharmacological approaches to treating negative symptoms: a review of clinical trials. Schizophr Res 150:346-352.
3. Arnt J (1995). Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of D-amphetamine. Eur J Pharmacol 283:55-62.
4. Barnett SA (1958). An analysis of social behaviour in wild rats. Proc Zoolog Soc (London) 130:107-152.
5. Becker A, Peters B, Schroeder H, Mann T, Huether G, Grecksch G (2003). Ketamine-induced changes in rat behaviour: a possible animal model of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 27:687-700.
6. Boulay D, Depoortère R, Louis C, Perrault G, Griebel G, Soubrié P (2004). SSR181507, a putative atypical antipsychotic with dopamine D2 antagonist and 5-HT1A agonist activities: improvement of social interaction deficits induced by phencyclidine in rats. Neuropharmacology 46:1121-1129.
7. Boyer P, Lecrubier Y, Puech AJ, Dewailly J, Aubin F (1995). Treatment of negative symptoms in schizophrenia with amisulpride. Br J Psychiatry 166:68-72.
8. Brenchat A, Romero L, García M, Pujol M, Burgueño J, Torrens A, et al. (2009). 5-HT7 receptor activation inhibits mechanical hypersensitivity secondary to capsaicin sensitization in mice. Pain 141:239-247.
9. Bruins Slot LA, Kleven MS, Newman-Tancredi A (2005). Effects of novel anti-psychotics with mixed D(2) antagonist/5-HT(1A) agonist properties on PCP-induced social interaction deficits in the rat. Neuropharmacology 49:996-1006.
10. Carnoy P, Ravard S, Wemerman B, Soubrie P, Simon P (1986). Behavioral deficits induced by low doses of apomorphine in rats: evidence for a motivational and cognitive dysfunction which discriminates among neuroleptic drugs. Pharmacol Biochem Behav 25:503-509.
11. Chindo BA, Adzu B, Yahaya TA, Gamaniel KS (2012). Ketamine-enhanced immobility in forced swim test: a possible animal model for the negative symptoms of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 38:310-316.
12. Danion JM, Rein W, Fleurot O (1999). Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group. Am J Psychiatry 156:610-616.
13. Davis MC, Horan WP, Marder SR (2014). Psychopharmacology of the negative symptoms: current status and prospects for progress. Eur Neuropsycho-pharmacol 24:788-799.
14. Duan TT, Tan JW, Yuan Q, Cao J, Zhou QX, Xu L (2013). Acute ketamine induces hippocampal synaptic depression and spatial memory impairment through dopamine D1/D5 receptors. Psychopharmacology (Berl) 228:451-461.
15. Engin E, Treit D, Dickson CT (2009). Anxiolytic-and antidepressant-like properties of ketamine in behavioral and neurophysiological animal models. Neuroscience 161:359-369.
16. Erickson CA, Stigler KA, Posey DJ, McDougle CJ (2010). Aripiprazole in autism spectrum disorders and fragile X syndrome. Neurotherapeutics 7:258-263.
17. File SE (1980). The use of social interaction as a method for detecting anxiolytic activity of chlordiazepoxide-like drugs. J Neurosci Methods 2:219-238.
18. File SE, Hyde J, Pool M (1976). Effects of ethanol and chlordiazepoxide on social interaction in rats [proceedings]. Br J Pharmacol 58:465P.
19. Foussias G, Agid O, Fervaha G, Remington G (2014). Negative symptoms of schizophrenia: clinical features, relevance to real world functioning and specificity versus other CNS disorders. Eur Neuropsychopharmacol 24:693-709.
20. Gururajan A, Taylor DA, Malone DT (2010). Current pharmacological models of social withdrawal in rats: relevance to schizophrenia. Behav Pharmacol 21:690-709.
21. Holuj M (2013). The aripiprazole but not sertindole or clozapine attenuated ketamine-induced schizophrenia-like social deficits in rats. 15th Biennal Meeting of the The European Behavioural Pharmacology Society (EBPS) 2013; La Rochelle, France. p. 35.
22. Horiguchi M, Huang M, Meltzer HY (2011). The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats. J Pharmacol Exp Ther 338:605-614.
23. Huang M, Horiguchi M, Felix AR, Meltzer HY (2012). 5-HT1A and 5-HT7 receptors contribute to lurasidone-induced dopamine efflux. Neuroreport 23:436-440.
24. Kirkpatrick B, Fenton WS, Carpenter WT Jr., Marder SR (2006). The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull 32:214-219.
25. Kocsis B, Brown RE, McCarley RW, Hajos M (2013). Impact of ketamine on neuronal network dynamics: translational modeling of schizophrenia-relevant deficits. CNS Neurosci Ther 19:437-447.
26. Koros E, Rosenbrock H, Birk G, Weiss C, Sams-Dodd F (2007). The selective mGlu5 receptor antagonist MTEP, similar to NMDA receptor antagonists, induces social isolation in rats. Neuropsychopharmacology 32:562-576.
27. Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, et al. (2003). H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28:519-526.
28. Krystal JH, D'Souza DC, Karper LP, Bennett A, Abi-Dargham A, Abi-Saab D, et al. (1999). Interactive effects of subanesthetic ketamine and haloperidol in healthy humans. Psychopharmacology (Berl) 145:193-204.
29. Krystal JH, Sanacora G, Duman RS (2013). Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol Psychiatry 73:1133-1141.
30. Leucht S, Pitschel-Walz G, Engel RR, Kissling W (2002). Amisulpride, an unusual 'atypical' antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 159:180-190.
31. Möller HJ, Boyer P, Fleurot O, Rein W (1997). Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group. Psychopharmacology (Berl) 132:396-401.
32. Natesan S, Reckless GE, Barlow KB, Nobrega JN, Kapur S (2008). Amisulpride the 'atypical' atypical antipsychotic-comparison to haloperidol, risperidone and clozapine. Schizophr Res 105:224-235.
33. Neill JC, Barnes S, Cook S, Grayson B, Idris NF, McLean SL, et al. (2010). Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. Pharmacol Ther 128:419-432.
34. Neill JC, Harte MK, Haddad PM, Lydall ES, Dwyer DM (2014). Acute and chronic effects of NMDA receptor antagonists in rodents, relevance to negative symptoms of schizophrenia: a translational link to humans. Eur Neuropsychopharmacol 24:822-835.
35. Newcomer JW, Farber NB, Jevtovic-Todorovic V, Selke G, Melson AK, Hershey T, et al. (1999). Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 20:106-118.
36. Nikiforuk A, Popik P (2013). Amisulpride promotes cognitive flexibility in rats: the role of 5-HT7 receptors. Behav Brain Res 248:136-140.
37. Nikiforuk A, Kos T, Fijal K, Holuj M, Rafa D, Popik P (2013). Effects of the selective 5-HT7 receptor antagonist SB-269970 and amisulpride on ketamine-induced schizophrenia-like deficits in rats. PLoS One 8:e66695.
38. Noda Y, Yamada K, Furukawa H, Nabeshima T (1995). Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phency-clidine: a new model of schizophrenia. Br J Pharmacol 116:2531-2537.
39. Perez-García GS, Meneses A (2005). Effects of the potential 5-HT7 receptor agonist AS 19 in an autoshaping learning task. Behav Brain Res 163:136-140.
40. Perrault G, Depoortere R, Morel E, Sanger DJ, Scatton B (1997). Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. J Pharmacol Exp Ther 280:73-82.
41. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ Jr., Shen Y, et al. (1994). Binding of typical and atypical antipsychotic agents to 5-hydro-xytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 268:1403-1410.
42. Sams-Dodd F (1995). Automation of the social interaction test by a video-tracking system: behavioural effects of repeated phencyclidine treatment. J Neurosci Methods 59:157-167.
43. Sams-Dodd F (1998). Effects of diazepam, citalopram, methadone and naloxone on PCP-induced stereotyped behaviour and social isolation in the rat social interaction test. Neurosci Biobehav Rev 23:287-293.
44. Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet O, et al. (1997). Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 280:83-97.
45. Silvestre JS, Nadal R, Pallarés M, Ferré N (1997). Acute effects of ketamine in the holeboard, the elevated-plus maze, and the social interaction test in Wistar rats. Depress Anxiety 5:29-33.
46. Snigdha S, Neill JC (2008a). Efficacy of antipsychotics to reverse phencyclidine-induced social interaction deficits in female rats-a preliminary investigation. Behav Brain Res 187:489-494.
47. Snigdha S, Neill JC (2008b). Improvement of phencyclidine-induced social behaviour deficits in rats: involvement of 5-HT1A receptors. Behav Brain Res 191:26-31.
48. Von Steiniger F (1950). Contribution to the sociology and other biology of the brown rat [in German]. Zeitschrift Fur Tier Psychologie 7:356-379.
49. Wesolowska A, Nikiforuk A, Stachowicz K, Tatarczyńska E (2006). Effect of the selective 5-HT7 receptor antagonist SB 269970 in animal models of anxiety and depression. Neuropharmacology 51:578-586.
50. Zugno AI, de Miranda IM, Budni J, Volpato AM, Luca RD, Deroza PF, et al. (2013). Effect of maternal deprivation on acetylcholinesterase activity and behavioral changes on the ketamine-induced animal model of schizophrenia. Neuroscience 248:252-260.